“Receipt of these quotas, together with the previously disclosed cultivation quotas, moves us measurably closer to our priority of serving patient needs in Colombia, and further jurisdictions in Latin America, said Khiron Vice-President of Regulatory Affairs Juan Diego Alvarez. “With our fast growing ILANS clinics and recently launched Zerenia clinic, we have a large and engaged patient network for chronic pain and nausea related conditions to immediately serve through medical cannabis.”

• Of the 9.3 tons approved, 50% are for Colombian domestic use and 50% are designated for export purposes.
• Export quotas allow for the manufacture of whole plant extract for international purposes to countries such as Peru, Uruguay and Brazil, Khiron says.
• Domestic quotas support the firm’s desire to bring the first medical cannabis products to market in Colombia, targeting patients with chronic pain and nausea associated with chemotherapy.

Based on high-THC medical cannabis demand, Khiron claims that it will be able to produce approximately a million bottles of high-THC formulation for medical use domestically in Colombia and abroad. The company said that it expects to receive final GEP laboratory certification in the near future.